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Aging exacerbates development of cerebral
microbleeds in a mouse model
Rachita K. Sumbria1,2, Mher Mahoney Grigoryan2, Vitaly Vasilevko3, Annlia Paganini-Hill2, Kelley Kilday3,
Ronald Kim4, David H. Cribbs3 and Mark J. Fisher2,4,5,6*

Abstract
Background: Cerebral microhemorrhages (CMH) are commonly found in the aging brain. CMH are also the
neuropathological substrate of cerebral microbleeds (CMB), demonstrated on brain MRI. Recent studies
demonstrate the importance of systemic inflammation in CMH development, but the relationships among
inflammation, aging, and CMH development are not well-defined. In the current study, we hypothesized that
the pathogenesis of inflammation-induced CMH in mice differs by age.
Methods: We studied young (3 months, n = 20) and old (18 months, n = 25) C57BL/6 mice injected with
low-dose lipopolysaccharide (LPS; 1 mg/kg, i.p.) or saline at 0, 6, and 24 h. Seven days after the first LPS/saline injection,
brains were harvested, sectioned, and stained with hematoxylin and eosin (H&E) and Prussian blue (PB) to estimate
acute/fresh and sub-acute CMH development, respectively. The relationships between microglial/macrophage
activation (ionized calcium-binding adapter molecule-1), astrocyte activation (glial fibrillary acidic protein),
blood-brain barrier (BBB) disruption (brain immunoglobulin G), aging, and CMH development were examined
using immunohistochemistry.
Results: Aging alone did not increase spontaneous H&E-positive CMH development but significantly increased
the number, size, and total area of LPS-induced H&E-positive CMH in mice. LPS- and saline-treated aged mice
had significantly larger PB-positive CMH compared with young mice, but the total area of PB-positive CMH
was increased only in LPS-treated aged mice. Aged mice had significantly increased microglial/macrophage
activation, which correlated with H&E- and PB-positive CMH development. Aged mice treated with LPS had
significantly increased astrocyte activation and BBB disruption compared with young LPS-treated mice.
Conclusions: Aging makes the brain more susceptible to inflammation-induced CMH in mice, and this increase in
CMH with aging is associated with microglial/macrophage activation.
Keywords: Animal models, Cerebral microhemorrhage, Cerebral microbleeds, Inflammation, Hemosiderin, Aging

Background
Age is the most significant independent risk factor for
cerebral microbleeds (CMB), which are identified by
brain MRI and have as their pathologic substrate cerebral microhemorrhages (CMH) [1, 2]. In addition to
aging, CMB are associated with hypertension, cerebral
amyloid angiopathy (CAA), Alzheimer’s disease, cerebral
autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), and chronic
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kidney disease, among other diseases [3–7]. Despite their
high prevalence and clinical importance, the mechanisms underlying age-related CMB increase are not wellunderstood. One mechanism suggested by clinical
findings is the activation of inflammatory cascades
followed by blood-brain barrier (BBB) damage resulting
in CMH development [8–11]. In fact, a pro-inflammatory
systemic state is a common factor observed in normal
aging and diseases with a high prevalence of CMB [12–15].
Recently, we showed that systemic inflammation induced by lipopolysaccharide (LPS) administration results in CMH development in mice and that CMH
development was associated with levels of systemic
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and neuroinflammatory markers [2, 16]. However, the
relationships among aging, inflammation, and CMH
development are not well-defined [3]. The current study
aimed to determine if aging exacerbates inflammationinduced CMH, and we hypothesized that the pathogenesis
of inflammation-induced CMH in mice differs by age. We
utilized the inflammation-induced CMH mouse model
which results in MRI-demonstrable CMB [2]. LPS was
used as the inflammatory stimulus to induce CMH development in young (3-month old) and aged (18-month old)
mice. Age-related changes in both hematoxylin and eosin
(H&E)-positive (acute) and Prussian blue-positive (subacute) CMH were examined in relationship to markers of
neuroinflammation and BBB damage.

Methods
Mouse treatment

All animal procedures were approved by the University
of California, Irvine, Institutional Animal Care and Use
Committee, and followed the ARRIVE Guidelines for
animal experiments reporting. Young (3-month old) and
aged (18-month old) C57BL/6 male and female mice
(National Institute of Aging, Bethesda, MD) were randomly assigned to two treatment groups: one treated
with a 1 mg/kg dose of LPS derived from gram-negative
bacterium Salmonella typhimurium (Sigma-Aldrich, St.
Louis, MO) and the other treated with saline intraperitoneally (i.p.) at three times at 0, 6, and 24 h. Seven days
after the first LPS/saline injection, mice were anesthetized with a lethal dose of Nembutal (150 mg/kg, i.p.),
cardiac perfusions were performed using ice-cold PBS,
and brains were processed for CMH detection as described in our previous work [16]. The sample size for
each group was as follows: young-saline = 10, agedsaline = 10, young-LPS = 10, and aged-LPS = 15. The
average weight of the mice was 28.1 ± 0.9 g at the beginning of the study and 27.1 ± 0.8 at the end of the study.
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Nuclear Fast Red (Sigma, St. Louis, MO), dehydrated,
and cover slipped. Remaining sections were used for immunohistochemistry. CMH were counted at a × 20 magnification by a blinded observer, and digitized images
were used to determine CMH size (μm2) and positive
area (expressed as a percent of total area analyzed), by
an observer blinded to the experiment using RGB CMH
analyzer program and NIH Image J software 1.62,
respectively [16].
IgG, Iba-1, and GFAP immunohistochemistry

Parenchymal IgG (BBB damage marker), Iba-1 (microglial/macrophage marker), and GFAP (astrocyte marker)
immunohistochemistry were performed [16]. Briefly, 40μm sections were incubated in 0.5% hydrogen peroxide
in 0.1 M PBS (pH 7.4) containing 0.3% Triton-X100
(phosphate-buffered saline with triton-X100 (PBST)) for
30 min at room temperature (RT), washed with PBST,
and blocked with PBST containing 2% bovine serum albumin for 30 min at RT. Sections were then incubated
overnight at 4 °C with a rabbit anti-mouse IgG antibody
(1:200 dilution; Jackson ImmunoResearch, West Grove,
PA), rabbit antibody against Iba-1 (1:200 dilution, Wako
Chemicals USA, Richmond, VA), or rabbit antibody
against GFAP (1:2000 dilution, Abcam, Cambridge,
MA). After washing with PBST, sections were incubated
at RT for 1 h with biotinylated anti-rabbit IgG (1:500 dilution; Jackson ImmunoResearch, West Grove, PA),
followed by 1 h incubation at RT with ABC complex,
and developed with 3,3′-diaminobenzidine (DAB) (Vector
Laboratories, Burlingame, CA) as per manufacturer’s instructions. Sixteen images per brain section were acquired
at × 20 magnification, and the total positive immunoreactive area (expressed as percent of total analyzed area) was
quantified using NIH Image J software 1.62 by an observer
blinded to the experimental groups [16].
Statistical analysis

Microhemorrhage detection

Right hemispheres were fixed in 4% paraformaldehyde
(Boston BioProducts, Ashland, MA) at 4 °C, examined
for surface CMH, and sectioned into 40-μm coronal sections using a vibratome (Technical Products International, Inc., St. Louis, MO). Every fourth, fifth, sixth,
and seventh section was collected. Every sixth section
was stained with H&E by Research Services Core offered
by the Department of Pathology and Laboratory Medicine at UCI Medical Center to detect fresh (acute)
CMH. Every seventh section was stained with Prussian
blue (PB) to detect hemosiderin (a marker of sub-acute
CMH) [16]. Briefly, sections were stained using 5% potassium hexacyanoferrate trihydrate (Sigma, St. Louis,
MO) and 5% hydrochloric acid (Sigma, St. Louis, MO)
for 30 min, rinsed in water and counterstained with

Based on our previous work showing a mean number of
CMH per brain section of 1.3 ± 0.8 in the LPS group and
0.03 ± 0.05 in the saline group, we estimated that at
least 10 mice per group were needed to detect a significant difference between LPS and control mice at 80%
power. One-way ANOVA with Bonferroni’s post hoc test
for normal data and Kruskal-Wallis with Dunn’s multiple comparison test for non-normal data were used to
compare more than two groups. Two-way ANOVA with
Tukey’s post hoc test was used for sex comparisons.
Pearson r correlation was used for correlation analysis.
One-sample t test was used to compare group means
with a hypothesized mean = 0 when the values in the
control group were zero (e.g., surface microhemorrhages). A two-tailed p value of < 0.05 was considered
statistically significant.
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Results
Survival

All the saline-treated young and aged mice and LPS-treated
young mice survived the duration of the study (n = 10 per
group). Four aged mice treated with LPS died prematurely
reducing the number included in the analysis to 15.
Cerebral microhemorrhages

Aging exacerbated the development of LPS-induced
surface CMH, and the number of surface CMH in LPStreated aged mice increased 23-fold compared with LPStreated young mice (Fig. 1a, e). No surface CMH were
observed in saline-treated mice, young or old.
In young mice, no spontaneous (in the absence of
LPS) H&E-positive acute CMH were observed in salinetreated mice and a 1 mg/kg triple dose of LPS did not
result in significant development of H&E-positive acute
CMH (Fig. 1b–d, f ). Aging did not cause a significant increase in spontaneous acute CMH development in
saline-treated mice; however, similar to the effect on surface CMH development, aging significantly increased the
development of H&E-positive acute parenchymal CMH
in LPS-treated mice (Fig. 1b–d, f ). All three parameters
(number, size, and total area) of H&E-positive acute parenchymal CMH were significantly increased with age in
LPS-treated mice (Fig. 1b–d). H&E-positive lesions were
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significantly higher in the cerebellum compared with the
cortex and the sub-cortex (data not shown).
The number of PB-positive sub-acute parenchymal
CMH was significantly higher in the LPS-treated young
and LPS-treated aged mice compared with their respective saline controls (Fig. 2a–c). The number of PBpositive CMH lesions increased twofold in LPS-treated
aged mice compared with LPS-treated young mice, although this increase did not reach statistical significance. Aging independently (with and without LPS)
caused a significant increase in PB-positive lesion size;
average size increased approximately threefold in both
saline- and LPS-treated aged mice compared with their
respective young controls (Fig. 2b). Total PB-positive
lesion area, which is a function of both lesion number
and size, was significantly increased with age in LPStreated mice (Fig. 2c). The number of H&E-positive
acute and PB-positive sub-acute lesions were significantly correlated (Pearson r = 0.92, p < 0.0001) in aged
mice (Fig. 2d) but not in young mice (data not shown).
Relationship between CMH development,
neuroinflammation, BBB damage, and aging

Aging was associated with a significant increase in
brain Iba-1-positive immunoreactivity, independent of
LPS treatment (Fig. 3a). Immunoreactive area of the

Fig. 1 Surface and acute H&E-positive cerebral microhemorrhages (CMH). No development of surface CMH in young and aged saline-treated mice
(n = 10 per group). Significant development of surface CMH in aged LPS-treated mice (n = 15) compared with young LPS-treated (n = 10) and aged
saline-treated mice (n = 10) (a). No development of acute (H&E-positive) parenchymal CMH in saline-treated young mice. Significantly greater number,
size, and total area of acute parenchymal CMH in LPS-treated aged mice compared with LPS-treated young mice and saline-treated aged mice (b–d).
Brain images showing development of surface CMH in LPS-treated aged mice compared with LPS-treated young mice (e). Representative images
showing acute CMH in different brain regions (f). Data are presented as mean ± SEM. One-sample t test for surface CMH, one-way ANOVA with
Bonferroni’s post-test, or Kruskal-Wallis test with Dunn’s post-test. *p < 0.05 and **p < 0.01. Scale bar = 100 μm
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Fig. 2 Sub-acute Prussian Blue (PB)-positive cerebral microhemorrhages (CMH). Significantly higher number of PB-positive lesions in LPS-treated
young (n = 10) and LPS-treated aged mice (n = 15) compared with their respective saline controls (n = 10 per group) (a). Significant increase in
PB-positive lesion size with aging (b). Significant increase in PB-positive total lesion area in LPS-treated aged mice compared with LPS-treated
young mice and saline-treated aged mice (c). PB-positive and H&E-positive lesion number are significantly correlated in aged mice (d). Representative
images showing PB-positive stains in different brain regions (e). Scale bar = 100 μm. Data are presented as mean ± SEM. One-way ANOVA with
Bonferroni’s post-test or Kruskal-Wallis test with Dunn’s post-test; *p < 0.05, **p < 0.01, and ***p < 0.001

Fig. 3 Neuroinflammation, BBB disruption, and CMH development. Significantly higher Iba-1-positive immunoreactivity with aging (a), and GFAP- (b)
and IgG- (c) positive immunoreactivity in LPS-treated aged mice compared with LPS-treated young mice. PB- and H&E-positive CMH numbers are
significantly correlated with Iba-1 positive immunoreactivity in aged mice (d, e). Representative images of Iba-1, GFAP, and IgG immunohistochemistry
(f). Data are presented as mean ± SEM. One-way ANOVA with Bonferroni’s post-test or Kruskal-Wallis test with Dunn’s post-test and Pearson correlation;
*p < 0.05, **p < 0.01, and ****p < 0.0001
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astrocyte activation marker (GFAP) and BBB damage
marker (brain IgG) on the other hand were significantly
increased with age only in LPS-treated mice (Fig. 3b, c).
Overall, both the H&E-positive and PB-positive lesion
numbers were significantly correlated with Iba-1-positive
immunoreactivity (Fig. 3d, e).
Sex and CMH development

In an exploratory analysis of the relationship between
sex and CMH development, the number (p < 0.01), size
(p < 0.0001), and total area (p < 0.01) of H&E-positive
acute parenchymal CMH were increased with age in LPStreated male mice compared with LPS-treated female aged
mice. No sex differences were observed in PB-positive
CMH and in markers of neuroinflammation and BBB injury among young or aged mice (data not shown).

Discussion
In the current study, we investigated the effect of aging
on inflammation-induced CMH development in a mouse
model. We demonstrated negligible spontaneous acute
CMH development in saline-treated young and aged
mice. Exacerbation of acute CMH development was observed in LPS-treated aged mice and not in LPS-treated
young mice. Since H&E staining enables the detection of
fresh or acute microhemorrhages in the brain [2], the
presence of fresh microhemorrhages in aged LPS-treated
mice suggests that inflammation-induced CMH development is an ongoing process that lasts days after the last
LPS injection in aged mice but not young mice (last LPS
injection at day 2 and sacrifice at day 7 in the current
study). PB on the other hand detects hemosiderin that
remains at the bleeding site for a prolonged period of
time, thus enabling the detection of cumulative CMH
load at the time of sacrifice.
LPS treatment resulted in significant development of
PB-positive sub-acute CMH in both young and aged
mice. Consistent with other findings and our own work,
we found low numbers of spontaneous PB-positive
CMH in young and aged mice [2, 17]. Total PB-positive
CMH load was significantly higher in LPS-treated aged
mice and not in LPS-treated young mice. Spontaneous
PB-positive CMH were significantly larger in aged mice,
but this effect was independent of LPS treatment. The
number of PB-positive lesions was highly associated with
the number of H&E-positive lesions (r2 = 0.85) further
suggesting that hemosiderin-positive sub-acute microhemorrhages detected by PB may help predict the susceptibility of the aging brain to develop acute or fresh
microhemorrhages. Taken together, these results show
that aging and inflammation together make the brain
more vulnerable to CMH development and further corroborate previous studies that support the role of inflammation in the pathogenesis of CMH [8, 9, 18].
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Though the exact molecular mechanisms underlying
inflammation-induced CMH development are not completely understood, loss of microvascular integrity associated with inflammatory changes is associated with
CMH development [19]. In the current study, we observed an increase in BBB disruption in LPS-treated
aged mice consistent with our previous work [16]. Systemic administration of LPS is known to result in BBB
injury and inflammation by altering tight junction protein expression, enlarging intercellular clefts, and increasing cytokine and chemokine release [20, 21]. These
effects of LPS are mediated by its binding to toll-like receptor 4 (TLR4), which activates signaling pathways implicated in BBB disruption [22]. The contribution of
TLR4 in intracerebral hemorrhage (ICH)-induced brain
injury and inflammation has been documented [23], and
a recent study showed that endothelial TLR4 activation
by its canonical ligand LPS accelerates cerebral cavernous malformations (CCM) [24]. Given the role of TLR4
activation in ICH and CCM development and increased
expression of TLR4 with the LPS dose used in the
current study [25], TLR4 activation via LPS may mediate
at least some of the effects observed in the current
study. Overall, increased LPS-mediated BBB disruption
in the current study further supports the role of the
inflammation-induced loss of BBB integrity in CMH development [11]; the underlying role of TLR4 in CMH
development needs further investigation. Loss of BBB integrity detected at the time of sacrifice in the aged mice
in the current study may further explain the presence of
acute CMH several days after the last LPS injection in
aged mice and not LPS-treated young mice.
Studies show that hemosiderin deposits in the brain
are often surrounded by macrophages which can further
initiate an inflammatory response [26]. Consistent with
this and our previous work, we found a significant increase in two different markers of neuroinflammation,
Iba-1 (microglial/macrophage activation marker) and
GFAP (astrocyte activation marker), in aged mice [2].
Iba-1 immunoreactivity was elevated with aging in the
current study and was independent of LPS treatment.
Further, we found that microglia/macrophage activation
was significantly associated with CMH development in
aged mice. We also found an increase in astrocyte activation in the aged mice treated with LPS, further indicating the increased susceptibility of the aging brain to
neuroinflammation.
The role of microglia/macrophages in the pathogenesis
of CMH is not well-defined. Apart from exhibiting a
cytotoxic phenotype (M1 phenotype), microglia/macrophages can also mediate repair mechanisms in the brain
depending on the brain microenvironment (M2 phenotype) [27, 28]. M2 macrophages are associated with
hematoma resolution after intracerebral hemorrhage in a
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mouse model [29]. Whether the macrophage/microglial
response to CMH observed in the current study is protective (clearing the CMH) or detrimental (triggering
local inflammation) needs further investigation.
Sex differences in CMB development have been reported in clinical settings and CMB are more prevalent in
males [30]. An exploratory analysis of our data showed
that LPS-treated aged male mice were more susceptible to
acute (H&E-positive) CMH development compared to
LPS-treated aged female mice. We observed no sex
differences in subacute (PB-positive) CMH development
in aged mice. These sex differences in LPS-induced CMH
development are consistent with prior observations on sex
differences in response to LPS [31]. We speculate that
inflammation-induced CMH development is an ongoing
process in aged male mice at the time of sacrifice (7 days),
compared with aged female mice. Future experimental
studies are needed to fully define this process.

Conclusions
The current study highlights the relationships among
aging, inflammation, and CMH development. Aging increases the susceptibility of the brain to inflammationinduced CMH development in mice, and this increase in
CMH development is significantly associated with
microglial/macrophage activation. The exact role of
microglial activation in CMH pathogenesis needs further
investigation.
Abbreviations
BBB: Blood-brain barrier; CAA: Cerebral amyloid angiopathy;
CADASIL: Cerebral autosomal-dominant arteriopathy with subcortical infarcts
and leukoencephalopathy; CCM: Cerebral cavernous malformations;
CMB: Cerebral microbleeds; CMH: Cerebral microhemorrhages; DAB: 3,3′Diaminobenzidine; GFAP: Glial fibrillary acidic protein; H&E: Hematoxylin and
eosin; Iba-1: Ionized calcium-binding adapter molecule-1; ICH: Intracerebral
hemorrhage; IgG: Immunoglobulin G; LPS: Lipopolysaccharide; PB: Prussian blue
Acknowledgements
We would like to thank Tuan Ngo, Gurjit Pannu, Jiwei Cheng, and Masood
Akram for their assistance.
Funding
Funding for this study was provided by a grant from NINDS: RO1 NS20989
(MJF and DHC).
Availability of data and materials
Community-established norms of data sharing are fully respected.
Authors’ contributions
RKS designed and performed experiments, analyzed data, prepared the
figures, and wrote the paper. MMG performed experiments and collected
data. VV and KK performed the Prussian blue and immunohistochemical
staining. APH helped with data analysis. RK provided expertise with mouse
brain histology. DHC participated in the conception of the study and was
involved in revising the manuscript critically for important intellectual content.
MJF conceived the study, designed and coordinated the experiments, and
helped in the drafting and editing of the manuscript. All authors read and
approved the final manuscript.

Page 6 of 7

Ethics approval
All animal procedures were approved by UCI Institutional Animal Care and
Use Committee and were carried out in compliance with University
Laboratory Animal Resources regulations. This work does not involve any
applicable consent to participate.
Consent for publication
Not applicable
Competing interests
Mark J. Fisher has received support from Boehringer-Ingelheim and Otsuka
Pharmaceutical Company (research grants).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1
Department of Biopharmaceutical Sciences, School of Pharmacy, Keck
Graduate Institute, Claremont, CA, USA. 2Department of Neurology, University
of California, Irvine, CA, USA. 3Institute for Memory Impairments and
Neurological Disorders, University of California, Irvine, CA, USA. 4Department
of Pathology and Laboratory Medicine, University of California, Irvine, CA,
USA. 5Department of Anatomy and Neurobiology, University of California,
Irvine, CA, USA. 6UC Irvine Medical Center, 101 The City Drive South,
Shanbrom Hall, Room 121, Orange, CA 92868, USA.
Received: 21 November 2017 Accepted: 7 February 2018

References
1. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman
R, Warach S, et al. Cerebral microbleeds: a guide to detection and
interpretation. Lancet Neurol. 2009;8(2):165–74.
2. Sumbria RK, Grigoryan MM, Vasilevko V, Krasieva TB, Scadeng M, Dvornikova
AK, et al. A murine model of inflammation-induced cerebral microbleeds.
J Neuroinflammation. 2016;13(1):218.
3. Ungvari Z, Tarantini S, Kirkpatrick AC, Csiszar A, Prodan CI. Cerebral
microhemorrhages: mechanisms, consequences, and prevention. Am J
Physiol Heart Circ Physiol. 2017;312(6):H1128–H43.
4. Li L, Fisher M, Lau WL, Moradi H, Cheung A, Thai G, et al. Cerebral
microbleeds and cognitive decline in a hemodialysis patient: case report
and review of literature. Hemodial Int. 2015;19(3):E1–7.
5. Lee JS, Ko K, Oh JH, Park JH, Lee HK, Floriolli D, et al. Cerebral microbleeds,
hypertension, and intracerebral hemorrhage in cerebral autosomaldominant arteriopathy with subcortical infarcts and leukoencephalopathy.
Front Neurol. 2017;8:203.
6. Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease:
innocent observation or key player? Brain. 2011;134(Pt 2):335–44.
7. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ,
Hofman A, et al. Prevalence and risk factors of cerebral microbleeds: the
Rotterdam Scan Study. Neurology. 2008;70(14):1208–14.
8. Miwa K, Tanaka M, Okazaki S, Furukado S, Sakaguchi M, Kitagawa K.
Relations of blood inflammatory marker levels with cerebral microbleeds.
Stroke. 2011;42(11):3202–6.
9. Shoamanesh A, Preis SR, Beiser AS, Vasan RS, Benjamin EJ, Kase CS, et al.
Inflammatory biomarkers, cerebral microbleeds, and small vessel disease:
Framingham Heart Study. Neurology. 2015;84(8):825–32.
10. Schreiber S, Bueche CZ, Garz C, Braun H. Blood brain barrier breakdown as
the starting point of cerebral small vessel disease?—new insights from a rat
model. Exp Transl Stroke Med. 2013;5(1):4.
11. van Nieuwenhuizen KM, Hendrikse J, Klijn CJM. New microbleed after
blood-brain barrier leakage in intracerebral haemorrhage. BMJ Case Rep.
2017. https://doi.org/10.1136/bcr-2016-218794
12. Dziedzic T. Systemic inflammation as a therapeutic target in acute ischemic
stroke. Expert Rev Neurother. 2015;15(5):523–31.
13. Rouhl RP, Damoiseaux JG, Lodder J, Theunissen RO, Knottnerus IL, Staals J,
et al. Vascular inflammation in cerebral small vessel disease. Neurobiol
Aging. 2012;33(8):1800–6.

Sumbria et al. Journal of Neuroinflammation (2018) 15:69

Page 7 of 7

14. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its
potential contribution to age-associated diseases. J Gerontol A Biol Sci Med
Sci. 2014;69(Suppl 1):S4–9.
15. Pauletto P, Rattazzi M. Inflammation and hypertension: the search for a link.
Nephrol Dial Transplant. 2006;21(4):850–3.
16. Sumbria RK, Vasilevko V, Grigoryan MM, Paganini-Hill A, Kim R, Cribbs DH,
et al. Effects of phosphodiesterase 3A modulation on murine cerebral
microhemorrhages. J Neuroinflammation. 2017;14(1):114.
17. Cacciottolo M, Morgan TE, Finch CE. Rust on the brain from microbleeds
and its relevance to Alzheimer studies: invited commentary on Cacciottolo
Neurobiology of Aging, 2016. J Alzheimers Dis Parkinsonism. 2016;6(6):287.
18. Romero JR, Preis SR, Beiser AS, DeCarli C, Lee DY, Viswanathan A, et al.
Lipoprotein phospholipase A2 and cerebral microbleeds in the Framingham
Heart Study. Stroke. 2012;43(11):3091–4.
19. Charidimou A, Werring DJ. A raging fire in acute lacunar stroke:
inflammation, blood-brain barrier dysfunction and the origin of cerebral
microbleeds. J Neurol Sci. 2014;340(1–2):1–2.
20. Banks WA, Gray AM, Erickson MA, Salameh TS, Damodarasamy M, Sheibani
N, et al. Lipopolysaccharide-induced blood-brain barrier disruption: roles of
cyclooxygenase, oxidative stress, neuroinflammation, and elements of the
neurovascular unit. J Neuroinflammation. 2015;12:223.
21. Ghosh A, Birngruber T, Sattler W, Kroath T, Ratzer M, Sinner F, et al.
Assessment of blood-brain barrier function and the neuroinflammatory
response in the rat brain by using cerebral open flow microperfusion
(cOFM). PLoS One. 2014;9(5):e98143.
22. Nagyoszi P, Wilhelm I, Farkas AE, Fazakas C, Dung NT, Hasko J, et al.
Expression and regulation of toll-like receptors in cerebral endothelial cells.
Neurochem Int. 2010;57(5):556–64.
23. Fang H, Wang PF, Zhou Y, Wang YC, Yang QW. Toll-like receptor 4 signaling
in intracerebral hemorrhage-induced inflammation and injury. J
Neuroinflammation. 2013;10:27.
24. Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N, et al. Endothelial
TLR4 and the microbiome drive cerebral cavernous malformations. Nature.
2017;545(7654):305–10.
25. Chung DW, Yoo KY, Hwang IK, Kim DW, Chung JY, Lee CH, et al. Systemic
administration of lipopolysaccharide induces cyclooxygenase-2
immunoreactivity in endothelium and increases microglia in the mouse
hippocampus. Cell Mol Neurobiol. 2010;30(4):531–41.
26. Rosidi NL, Zhou J, Pattanaik S, Wang P, Jin W, Brophy M, et al. Cortical
microhemorrhages cause local inflammation but do not trigger widespread
dendrite degeneration. PLoS One. 2011;6(10):e26612.
27. Min H, Jang YH, Cho IH, Yu SW, Lee SJ. Alternatively activated braininfiltrating macrophages facilitate recovery from collagenase-induced
intracerebral hemorrhage. Mol Brain. 2016;9:42.
28. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG.
Identification of two distinct macrophage subsets with divergent effects
causing either neurotoxicity or regeneration in the injured mouse spinal
cord. J Neurosci. 2009;29(43):13435–44.
29. Ni W, Mao S, Xi G, Keep RF, Hua Y. Role of erythrocyte CD47 in intracerebral
hematoma clearance. Stroke. 2016;47(2):505–11.
30. Jeerakathil T, Wolf PA, Beiser A, Hald JK, Au R, Kase CS, et al. Cerebral
microbleeds: prevalence and associations with cardiovascular risk factors in
the Framingham Study. Stroke. 2004;35(8):1831–5.
31. Cai KC, van Mil S, Murray E, Mallet JF, Matar C, Ismail N. Age and sex
differences in immune response following LPS treatment in mice. Brain
Behav Immun. 2016;58:327–37.

Submit your next manuscript to BioMed Central
and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit

